Premium
Serum level of sELAM‐1 in psoriatic patients correlates with disease activity
Author(s) -
Krasowska Dorota,
Pietrzak Aldona,
LecewiczTorun Barbara
Publication year - 1999
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.1999.tb01004.x
Subject(s) - medicine , psoriasis , disease , endothelium , cell adhesion molecule , gastroenterology , immunology , pathology
Background Endothelial leucocyte adhesion molecule‐1 (ELAM‐1) acts as an adhesion ligand for neutrophils and monocytes and the expression of this molecule on the vascular endothelium may reflect its ability to recruit neutrophils from circulation. The next step is the transendothelial migration of neutrophils into lesional psoriatic skin. ELAM‐1 may also exist in a soluble form. Methods We determined the serum levels of ELAM‐1 by ELISA in 41 patients with psoriasis and 20 controls. Results Patients with acute psoriasis displayed higher levels of ELAM‐1 (85.45 ± 47.72 ng/ml) than controls (36.02 ± 15.60 ng/ml) and patients with chronic disease (61.24 ± 27.91 ng/ml). In 25 patients we measured the serum level of ELAM‐1 twice: at the beginning and after treatment of the disease and we did not find any significant changes. We also found a correlation between serum ELAM‐1 and PASI score. Conclusions These data suggest that there is a high serum level of E‐selectin in psoriatic subjects even after clearing of the disease. Serum E‐selectin may reflect the general activation of endothelial cells in the disease and may be a new sensitive marker of disease activity.